Artiva Biotherapeutics, Inc. (ARTV) vs CapsoVision, Inc. (CV)
A side-by-side comparison of Artiva Biotherapeutics, Inc. and CapsoVision, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARTV
Artiva Biotherapeutics, Inc.
$7.28HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
CV
CapsoVision, Inc.
$6.43HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — ARTV vs CV
growth of $100 · dividends reinvested · last 1yARTV +348.4% (+348.4%/yr)CV +88.3% (+88.3%/yr)ARTV compounded faster over this window
ARTV CV
ARTV vs CV: by the numbers
- •ARTV is the larger company ($356M vs $321M market cap).
- •Both run net losses; ARTV's is the smaller (0.00% vs -214.74% net margin).
Metrics side by side
Valuation
| Metric | ARTV | CV |
|---|---|---|
| P/S ratio | N/A | 23.13 |
| P/B ratio | 1.02 | 24.40 |
Profitability
| Metric | ARTV | CV |
|---|---|---|
| Gross margin | 0.00% | 50.88% |
| Operating margin | 0.00% | -188.25% |
| Net margin | 0.00% | -214.74% |
| ROE | -26.14% | -226.56% |
| ROIC | -27.16% | -164.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.